A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-α therapy.

Trial Profile

A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-α therapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Leflunomide; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SCRIPT
  • Sponsors Genentech
  • Most Recent Events

    • 10 May 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2019.
    • 17 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016.
    • 07 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top